SecBot SecBot
SECBOTREPLAY Home › Report › CRMD

CRMD · CorMedix issued a business update ahead of its Q3 2026 earnings call,…

CorMedix, Inc. · PRESS-RELEASE filed Nov 2, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 2, 2026 at 07:30 ET

CorMedix issued a business update ahead of its Q3 2026 earnings call, reaffirming full-year 2026 revenue guidance of $325M-$345M and reporting $355M cash on hand. The CMS 2027 ESRD final rule set a Q1 2027 DefenCath add-on of $8.32 per session, within the company's previously guided 3x-5x range above the current $2.37 rate, and management provided qualitative commentary on the expected quarterly trajectory of the add-on for 2027.

  • Cash and cash equivalents as of September 30, 2026: approximately $355 million.
  • Full-year 2026 total revenue guidance reaffirmed at $325M-$345M.
  • CMS 2027 ESRD final rule provides a Q1 2027 DefenCath post-TDAPA add-on of $8.32 per dialysis session.
  • Q1 2027 add-on of $8.32 is within the company's previously guided range of 3x-5x higher than the current $2.37 rate.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access